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Introduction 
Efficient, but safe, pharmacological aids to weight loss is the holy grail of obesity research.  From the 
public health point of view, it is concerning that hazards of the past seem to be a permanent or 
returning feature of today’s off-street 'supplement' market, mainly through retail networks that fall 
outside standard safety regulations: the Internet 1.  2,4-Dinitrophenol (DNP) was used until the late 
1930s to treat obesity and was subsequently withdrawn owing to its severe toxicity2.  However, 
industrial uses of DNP as a dye, wood preserver, herbicide and film-developer have remained in 
place over the years.  Recently, DNP has resurfaced as a weight loss product in the supplement 
market as Su/olfo Black, Nitro Kleenup or Caswell No.392,3 but also sold on the Internet or listed 
among the ingredients as Aldifen, Chemox, Nitophen, Dinofan, Dinosan, Dnoc, Osmotox-, Fenoxyl-, or 
Tertosulphur PRB.  In parallel with the re-appearance of DNP as a weight-loss promoting agent, 
clinical presentations with DNP toxicity increased with associated high mortality worldwide4-6. 
Evidence from Internet forums and discussion boards suggests that DNP is widely used among 
bodybuilders to further reduce the often already low body fat percentage. To a lesser extent, DNP 
also appears to be in the repertoire of those with disordered eating, mainly restricted eaters and 
binge eaters, to counterbalance the calorie intake. 
DNP is a fat burner that inhibits efficient energy (ATP) production in cells.  Through uncoupling 
mitochondrial oxidative phosphorylation by facilitating proton transport across the mitochondrial 
membrane, DNP leads to rapid consumption of energy without generating ATP and consequently, to 
increased fat metabolism3,4.  However, the weight-loss effect comes with serious, and in some cases 
potentially fatal, adverse side effects.  These include hyperthermia (the leading cause of fatality with 
acute DNP toxicity) and cardiac arrest, but also diaphoresis, tachycardia, tachypnea; and cataracts 
with low dose chronic exposure2-6.   
With the persistent supply and popularity of DNP among bodybuilders and extreme dieters, regulatory 
efforts to prevent DNP use7,8 are undermined by readily available retail options on the Internet.  One 
alternative approach to mitigate health risks people willingly take with unknown, unlicensed and 
potentially dangerous substances is to devise end-user-centred, proactive public health policies.  In 
order to do this, it is important to understand the factors that affect an individual’s willingness to take 
the drug after acknowledgement of the adverse side effects.  Therefore, the aims of this study were to 
examine the different risk levels individuals are willing to take with DNP for the desired results and to 
investigate psychosocial factors that may influence risk willingness. 
Participants were recruited opportunistically through social networks with no specific 
inclusion/exclusion criteria for diet or weight. The final sample consisted of 150, mainly young, 
adults with mean age of 25.0 ± 5.4 years; age range 18-45 (88% being 30 years of age or younger);  
50% male; 32.7% white, 15.3% black, 18.0% Asian, 12.7% mixed, 21.3%  other ethnic background.  
The highest single proportion of the participants had an undergraduate degree (30.0%), followed by 
completed undergraduate Level 5 (26.7%), A-level/B-Tech (16.7%), GCSE (11.3%), postgraduate 
qualification (10.7%) and undergraduate Level 4 (4.7%).   
The survey contained questions about satisfaction with weight and desired change (if not satisfied 
with current weight) and measured general risk propensity9, global self-esteem10 and DNP-specific 
risk willingness.  Willingness to take risks with DNP was measured with three scenarios representing 
incremental levels of health risk: (i) guaranteed weight loss up to 8-10 kg in 2 months with no side 
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effect mentioned; (ii) as in (i) but some side effects including dehydration, headaches, sweating, 
discomfort, fever and/or flushed skin are known; and (iii) as in (i) but also aware that continual usage 
of DNP through a long period of time could cause death through abnormally high temperature 
(hyperthermia), high heart rate (tachycardia), excess sweating (diaphoresis) and rapid breathing 
(tachypnoea). The scenarios were individually rated on an 11-point scale which was anchored at 0 = 
not at all willing and 10 = very willing to take risk.   
Past experience with weight-loss products (excluding meal replacements) was recorded as presence 
or absence.  Self-reported satisfaction with current weight was assessed with a single question "Are 
you happy with your current weight?", with three answer options of 'Yes', 'No, I would like to lose 
weight' and 'No, I would like to gain weight' to cater for all possibilities. In case of 'No' answer, the 
magnitude of the discrepancy between current and desirable weights was recorded in incremental 
categories of 2kg, 4kg, 6kg, 10kg and > 10kg. Demographic information included age, sex, ethnicity 
and highest educational level.  To create a single score to facilitate comparison, an overall score for 
DNP risk willingness was calculated by weighting the expressed level of willingness in the three 
scenarios by 1, 2 and 4 respectively in increasing order of risk severity, then adding the weighted 
scores together to form a scale with a theoretical range of 0 to 70 (Cronbach alpha = 0.781).   
Weight satisfaction and past experience with weight-loss drugs other than DNP 
Of the 150 participants, only 20.7% (23 males and 9 females) were happy with their current weight.  
A further 6.7% (8 males and 2 females) wanted to gain weight.  The remaining 73.3% (44 males and 
64 females) reported weight-loss as a desirable goal.  Thirty-seven participants (24.7% of the sample; 
15 female and 22 male) reported having previous experience with weight-loss drugs.  
Based on sample characteristics, three distinct clusters were identified using two-step clustering 
with maximum likelihood method and Akaike's Information Criterion.  Predictor variables for cluster 
membership, in decreasing order of importance, were: satisfaction with weight (1.00), having past 
experience with weight-loss drugs (0.92), magnitude and direction of desired weight change (0.90), 
general risk propensity (0.08) and global self-esteem (0.05). The obtained importance scores, which 
range between 0 and 1 reflecting relative importance (1 being very important), show that the key 
discriminating factor is the desired goal and the magnitude of weight change and having past 
experience with weight-loss drugs.  Personality traits did not have discriminative power. 
The first group (Cluster 1) contained 41 people (mean age = 24.59 ± 5.12 year; 73.2% male) who 
were mainly either satisfied with their weight (78.0%) or wanted to gain weight (9.8%).  The majority 
(90.2%) had previous experience with weight-loss drugs and the average desired weight change, if 
any, was small (up to 2 kg).  The largest group (Cluster 2) comprised of 75 people (mean age = 24.93 
± 6.12; 34.7% male) who all wanted to lose between 4 to 6 kgs of weight but none had previous 
experience with weight-loss drugs.  The third distinct group (Cluster 3) formed with 33 people (mean 
age = 24.91 ± 4.09 years, 54.5% male) who all wanted to lose 6 kgs of weight or more and all had 
previous experience with weight-loss drugs.  The difference in DNP risk willingness between the 
three clusters were statistically significant (F(2,149) = 20.626, p < .001), with Cluster 1 exhibiting the 
lowest overall willingness to use DNP (2.80±4.77), followed by Cluster 2 (12.73±13.66) with a highest 
level of expressed willingness in Cluster 3 (20.18±13.04).  There was a notable variation in each 
group. The distribution of the willingness scores were skewed toward unwillingness in Clusters 1 and 
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2, but followed normal distribution in Cluster 3 (Kolmogorov-Smirnov tests with Lillefors correction, 
KS= 0.356, p < .001; 0.176, p < .001 and 0.137, p = .121, respectively). 
DNP risk willingness 
As expected, the overall DNP risk willingness decreased with the increase in health consequences: 
no side effects (4.83/10); some unpleasant but not fatal side effects (2.19/10) and potentially fatal 
side effects (0.59/10) for the full sample.  However, desire to lose weight influenced people's 
willingness to take risk with DNP (Fig 1A).  Detailed investigation further revealed a notable trend for 
gender (Fig 1B) and past experience (Fig 1C).  Female participants appeared to be more vulnerable to 
DNP-risk (t(129.8) = 2.981, p = .003).  Past experience facilitated higher willingness with DNP.  The 
mediation effect (path model), which was tested using structural equation modeling with maximum 
likelihood estimation using AMOS v22, showed weak partial mediation of past experience on the 
relationship between desired weight loss and willingness to use DNP (using the weighted overall 
score).  The regression weight from desired weight loss to willingness (B = 3.151 [standardised = 
.328]; SE = 0.777, p < .001) decreased but remained significant with past use interrupting the direct 
path (B = 2.902 [standardised B = .302], SE = 0.740, p < .001). The regression weights from past use 
to willingness was statistically significant (B = 9.269 [standardised B= .303]; SE = 2.261; p < .001).  
The similar regression weights from past use and desired weight change to DNP risk willingness 
suggest that the desired weight loss and having past experience exert equal influence on 
hypothetical willingness to take risks with DNP. (The relationship between desired weight loss and 
past use was small and non-significant.)  Ethnicity or education did not have an effect on willingness 
(F(4,145) = 0.506, p = .731, 2 = .014 and F(5,144) = 1.140, p = .213, 2 = .048, respectively).   
Relationship between demographics, personality traits and DNP risk willingness 
General risk propensity only showed weak positive correlation (expressed as Spearman rs) with DNP 
risk willingness (r = .242, p = .003) and a non-significant relationship with desired weight change (r = 
.115, p = .164).  Global self-esteem and age were independent of the DNP risk (r = .134, p = .101 and 
r = -.009, p = .917, respectively) or desired weight change (r = .055, p = .502; ; r = -.054, p = .513, 
respectively).  A much stronger relationship was observed between DNP risk willingness and the 
desired weight change (r = - .523, p < .001).  The negative correlation is explained by the coding: the 
more weight people wished to lose, the higher risk was that they were willing to take with DNP.   
Discussion 
The general trend if health consequences are known was negative because most participants were 
unwilling, to some degree, to take DNP. However, willingness showed an inverse relationship with 
the severity of the health consequences.  Willingness to take risks with DNP, despite health 
warnings,  appears to be influenced more by the desired goal (weigh-loss) and the magnitude of 
weight people wish to lose as well as having past experience with weight-loss drugs rather than their 
general risk-taking propensity or other psychosocial factors.  Ethnicity or education did not have an 
effect on willingness.  Possibly because of a highest level of weight dissatisfaction, female 
participants appear to be more vulnerable to DNP-risk.  However, the highest level of willingness to 
take risks with DNP, an unlicensed and dangerous chemical, was reported in a group that was 
characterised by the large amount of desired weight loss and having past experience with weight-
loss drugs, regardless of gender. With the caveat that hypothetical choices cannot be directly 
5 
 
extrapolated to actual decisions, it is notable that the willingness to use such a drug is present if 
health warnings are not known or potentially can be somehow discredited (e.g., used similar drugs 
before without problems, following 'expert advice' of those used the drug before or not exceeding 
recommended dose).  This may be explained by compensatory belief mechanism, which warrant 
further investigation in exploring in relation to DNP or other health-risks associated with weight loss 
products and unlicensed substances.   
Perspectives 
Although the reported level of risk that people from the general population were willing to take was 
low, the willingness to take risks increased with the desired weight-loss and by having past 
experiences with weight-loss drug(s).  Future studies should explore the level of willingness among 
specific populations such as bodybuilders and extreme dieters. Effective prevention should move 
beyond knowledge-based intervention (such as issuing health warnings regarding DNP) and tackle 
the motives behind the potentially risky behaviour with unknown or unlicensed drugs.  To facilitate 
this, future investigation should focus on the cognitive process of conflicting information in the 
context of weight-related goals and past experiences, along with associated risk perception, 
compensatory belief mechanism (particularly in the light of the elevated risk willingness if past 
experience with similar drugs are available) and trust in information sources and purchase options.   
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Fig 1: Level of willingness people are prepared to take with 2,4-Dinitrophenol (DNP) in the context of 
risk severity and participants’ psychosocial characteristics. (A) Risk willingness with DNP in groups 
based on satisfaction with current weight, desired weight loss goal and past experience with weight-
loss drugs in the full sample (n = 150) and (B) by gender and (C) experience in the subsample of 
participants desire weight loss (n = 108).  Error bars represents standard deviations; different letters 
denote significant difference at p < .05. 
 
